The integration of MpMRI with parameters like PSA density (dPSA) has shown remarkable promise in reducing unnecessary biopsies and enhancing local staging accuracy, marking a substantial advancement in prostate cancer management [6,7]. This evidence concerns the gene KLK3 and prostate carcinoma.